Boston Scientific Corporation is facing an 11% decline in share price despite a robust 13% growth in net income, coinciding with its recent $1.75 billion acquisition of Baylis Medical Company aimed at enhancing its product offerings. The company has raised its operational growth expectations to 9-11%, driven by substantial sales in cardiology and other sectors, although its return on equity lags behind the industry average. Additionally, Boston Scientific reported a $74 million revenue hit from foreign exchange, yet its overall stock performance continues to outperform the broader industry.
“Boston Scientific · has had a share price · down · 11%”
“Boston Scientific · has a ROE · of · 4.8%”
“Boston Scientific · has a net income growth · of · 13%”
“Boston Scientific · has an industry average ROE · of · 11%”
“Boston Scientific · has an industry average growth · of · 16%”
“Boston Scientific · does not pay any dividend · meaning · all of its profits are being reinvested”
“Boston Scientific · has positive aspects · to its business · true”
“Boston Scientific Corporation · has a market capitalization of · $54.28 billion · true”
“Boston Scientific · earnings for the first quarter of 2022 topped the Zacks Consensus Estimate by · 2.6% · true”
“Boston Scientific · experienced a stock decline of · 11.5% · true”
“Boston Scientific · raised its 2022 operational growth expectation to · 9-11% · true”
“Boston Scientific · acquired Baylis Medical Company for · $1.75 billion · true”